Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 1, 1991 - Issue 5
Journal homepage
12
Views
0
CrossRef citations to date
0
Altmetric
Anti-Inflammatory, Anti-Allergic, Respiratory & GI Agents

Overview: New Directions in Inflammatory Bowel Disease Therapy

Brian Carlson Krancer Center for Inflammatory Bowel Disease Research, Division of Gastroenterology, Department of Medicine, Hahnemann University, Philadelphia, PA 19102, USA
&
SNS Murthy Krancer Center for Inflammatory Bowel Disease Research, Division of Gastroenterology, Department of Medicine, Hahnemann University, Philadelphia, PA 19102, USA
Pages 615-629 | Published online: 02 Mar 2011

Key References

  • Sharon, P Stenson, WF Enhanced synthesis of LTB4 by colonic mucosa in IBD. Gastroenterology 1984 86 453–460.
  • Sharon, P Stenson, WF Metabolism of arachidonic acid in acetic acid colitis in rats: Similarity to human IBD. Gastroenterology 1985 88 55–63.
  • Zipser, RD Nast, CC Lee, M In vivo production of LTB4 and LTC4 in rabbit colitis. Relationship to inflammation. Gastroenterology 1987 92 33–39.
  • Bronghton-Smith, NK Wallace, JL Morris, GP Whittle, BJR The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of IBD in the rat. Br. J. Pharmacol. 1988 94 65–72.
  • Wallace, JL MacNaughton, WK Morris, GP Beck, PL Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989 96 29–36.
  • Baron, JH Connell, AM Lennard-Jones, JE Avery Jones, F Sulfasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962 1094–1096.
  • Dick, AP Grayson, MJ Carpenter, RG Petrie, A Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964 5 437–442.
  • Misiewicz, JJ Lennard-Jones, SE Connell, AM Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965 1 185–188.
  • Harris, DW Smith, PR Swan, CHJ Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease. Gut 1978 19 875–877.
  • Nielsen, OH Bukhare, K Elmgreen, J Ahnfelt-Ronne, I Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicyclic acid. Dig. Dis. Sci. 1987 32 577–582.
  • Stenson, WF Lobos, E Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J. Clin. Invest. 1982 69 494–497.
  • Miyachi, Y Yoshioka, A Imamura, S Niwa, Y Effect of sulfasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987 28 190–195.
  • Aruoma, OI Wasil, M Halliwell, B The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem. Pharmacol. 1987 36 3739–3742.
  • Azad Khan, AK Piris, J Truelove, SC An experiment to determine the actual therapeutic moiety of sulphasalazine. Lancet 1977 2 892–895.
  • Hawkey, CJ Salicylates for the sulfa-sensitive patient with ulcerative colitis. Gastroenterology 1986 90 1082–1084.
  • Riley, SA Lecarpentier, J Mani, V Sulphasalazine induced seminal abnormalities in ulcerative colitis: Results of mesalazine substitution. Gut 1987 28 1008–1012.
  • Campieri, M Lanfranchi, GA Bazzochi, G Treatment of ulcerative colitis with high dose 5-aminosalicyclic acid enemas. Lancet 1981 2 270–271.
  • Sutherland, LR Martin, F Greer, S 5-aminosalicyclic acid enemas in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92 1844–8.
  • Danish 5-ASA Group Topical 5-aminosalicyclic acid vs. prednisolone in ulcerative proctosigmoiditis. A randomized double-blind multicenter trial. Dig. Dis. Sci. 1987 32 591–602.
  • Ginsberg, AL Beck, LS McIntosh, TM Nochomovitz, LE Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial. Ann. Intern. Med. 1988 108 195–199.
  • Gandolfo, J Farthing, F Powers, G 4-Aminosalicylic acid retention enemas in the treatment of distal colitis. Dig. Dis. Sci. 1987 32 700–704.
  • Meyers, S Sachar, DB Present, DH Janowitz, HD Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987 93 1255–1262.
  • Rasmussen, SN Bondesen, S Hvidberg, EF 5-Aminosalicylic acid in a slow-release preparation: Bioavailability, plasma level, and excretion in humans. Gastroenterology 1982 83 1062–1070.
  • Chan, RP Pope, DJ Gilbert, AP Studies of two novel sulfasalazine analogues, ipsalazide and balsalazide. Dig. Dis. Sci. 1983 28 609–615.
  • Hawkey, CJ Truelove, SC Effect of prednisolone on prostaglandin synthesis by rectal mucosa in ulcerative colitis, investigation by laminar flow bioassay and radioimmunoassay. Gut 1981 22 190–193.
  • Kumana, CR Seaton, T Meghi, M Beclamethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing's syndrome or hypothalamic pituitary adrenal suppression. Lancet 1982 1 579–583.
  • Danielsson, A Hellers, G Lyrenas, E A controlled randomised trial of budesonide vs. prednisolone retention enemas in active distal ulcerative colitis. Scand. J. Gastroenterol. 1987 22 987–992.
  • Hanauer, SB Kirsner, JB Barrett, WE The treatment of left-sided ulcerated colitis with tixocortol pivalate. Gastroenterology 1986 90 1449.
  • DeKaskj, MC Hodgson, HJF Fluticasone propionate in inflammatory bowel disease. Can. J. Gastroenterology 1990 4 417–419.
  • Lock, TY Chang, JY Glaser, KB Inhibition of PAF and LTB4 biosynthesis in human neutrophils by putative PLA2 and 5LO inhibitors. Inflammation Research Association 1990 5th International Poster Session, Abstract #75.
  • Marshall, LA Bologenase, B Gelb, M Phosponate-phospholipid analogues inhibit human PLA2. 5th International Poster Session Inflammation Research Association 1990 Abstract #83.
  • DiVries, GW Lee, G Amdahl, H AGN 190383, a novel phospholipase inhibitor with topical anti-inflammatory activity. 5th International Poster Session Inflammation Research Association 1990 Abstract #69.
  • Lauritsen, K Laursen, LS Bukhave, K Rask-Madsen, J Effects of typical 5-ASA and prednisolone on PGE2 and LTB4 levels determined by equilibrium dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986 91 837–844.
  • Gould, SR Brash, AR Connolly, ME Lennard-Jones, JE Studies of prostaglandins and sulfasalazine in ulcerative colitis. Prostaglandin Med. 1981 6 165–182.
  • Campieri, M Lanfranchi, GA Bazzocchi, G Prostaglandin, indomethacin and ulcerative colitis. Gastroenterology 1980 78 193.
  • Miller, TA Jacobsen, ED Gastrointestinal cytoprotection by prostaglandins. Gut 1979 20 75–87.
  • Higgs, GA Flower, RJ Vane, JR A new approach to anti-inflammatory drugs. Biochem. Pharmacol. 1979 28 1959–1961.
  • Broughton-Smith, NK Wallace, JL Morris, GP Whittle, BJR The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br. J. Pharmacol. 1988 94 65–72.
  • Proudman, KE McMillan, RM Are tenidap and tolfenamic acid dual inhibitors of cycloxygenase and 5-lipoxygenase? 5th International Poster Session Inflammation Research Association 1990 Abstract #95.
  • Schumert, R Towner, J Zipser, RD Role of eiosannoids in human and experimental colitis. Dig. Dis. Sci. 1988 33 58S–64S.
  • Bouclier, M Shroot, B Maignan, J In vitro and in vivo anti-inflammatory properties of 2 unsaturated fatty acid derivatives: CD554 and CD581. 5th International Poster Session Inflammation Research Association 1990 poster #108.
  • Wallace, JL Keenan, CM A selective, orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of IBD. Gastroenterology 1989 196 A535.
  • Young, PR Bell, RL Lanni, C The rat peritoneal anaphylaxis model: Inflammatory mediators, systemic effects and the inhibitory activity of Zileuton. 5th International Poster Session Inflammation Research Association 1990 Abstract #80.
  • Sirois, P Borgeat, P Lauziere, M Inhibition of human 5-lipoxygenase ex vivo by compound A64077. 5th International Poster Session Inflammation Research Association 1990 Abstract #89.
  • Rask-Madsen, J Lauritsen, K Laursen, LS Abbott-64077, a potent lipoxygenase inhibitor in the treatment of ulcerative colitis. Gastroenterology 1990 96 A185.
  • Laursen, LS Naesdal, J Selective 5-LO inhibition in patients with ulcerative colitis: Effects of Abbott-64077. Gastroenterology 1990 96 A185.
  • Guindon, Y Girard, Y Mayrock, A L-651392, a novel potent and selective 5-lipoxygenase inhibitor Advances in prostaglandin, thromboxane, and leukotriene research. Samuelson, B, Pasletti, R, Ramwell, PN Raven New York 1987 Vol. 17A 447–454.
  • Wallace, JL Beck, PL Morris, GP Is there a role for leukotrienes as mediator of ethanolinduced gastric mucosal damage? Am. J. Physiol. 1988 245 G117–123.
  • Wallace, JL McNaughton, WK Morris, GP Beck, PL Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989 96 29–36.
  • Kargman, S Reid, GK Vickers, PJ Correlation between 5-lipoxygenase (5-LO), 5-LO activating protein (FLAP), leukotriene (LT) synthesis and inhibition of 5-LO translocation with LT biosynthesis inhibitors in HL-60 cells. 5th International Poster Session Inflammation Research Association 1990 Abstract #81.
  • Yagaloff, K Franco, L Essential fatty acids inhibit leukotriene B4 binding in pig neutrophils. 5yh International Poster Session Inflammation Research Association 1990 Abstract #4.
  • Welsh, RE Anglin, CP Baron, D Efficacy of the anti-inflammatory agent SC-41930 in a rat model of ileitis. 5th International Poster Session Inflammation Research Association 1990 Abstract #147.
  • Villani-Price, D Kachur, JF Anderson, AN Inhibition of neutrophil-endothelid cell interactions by the leukoturine B4 receptor antagonist SC 41930. 5th International Poster Session Inflammation Research Association 1990 Abstract #15.
  • Villani-Price, D Yang, DC Fretland, DJ Multiple actions of the leukotrine B4 receptor antagonist SC-41930. 5th International Poster Session Inflammation Research Association 1990 Abstract #16.
  • Majerus, PW Arachidonate metabolism in vascular disorders. J. Clin. Invest. 1983 72 1521–1525.
  • Ligumski, M Karmeli, F Sharon, P Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981 81 444–449.
  • Hawkey, CJ Karmeli, F Rachmilewitz, D Imbalance of prostacyclin and thromboxane A2 synthesis in Crohn's disease. Gut 1983 24 881–885.
  • Lauritsen, K Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease. Dan. Med. Bull. 1989 36 378–393.
  • Murthy, SNS Yun, E Brill, K Cooper, H Plasma TXB2 levels are preferentially increased during the 'acute' phase of DSS-mediated colitis in mice. Gastroenterology 1991 100 A602.
  • Peskar, BM Weiler, D Kroner, EE Peskar, SA Release of prostaglandins by small-intestinal tissue of man and rat in vitro and the effect of endotoxin in the rat in vivo. Prostaglandin 1981 21 9–14 (Suppl.)
  • Hawkey, CJ Broughton-Smith, NK Whittle, BJR Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig. Dis. Sci. 1985 30 1161–1165.
  • Stenson, WF Lobos, E Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem. Pharmacol. 1983 32 2205–2209.
  • Marceau, F de Blois, D Laplante, C Contractile effect of the chemostatic factors f-Met-Leu-Phe and CS5a on the human isolated umbilical artery. Role of cyclooxygenase products and tissue macrophages. Cir. Res. 1990 67 1059–1070.
  • Longhofer, SL Johnson, HC Culham, CA Effects of a specific thromboxane synthetase inhibitor on thromboxane A2 generation and excretion in healthy dogs. Am. J. Vet. Res. 1990 51 1746–1750.
  • Shiranhase, H Vsui, H Shimaji, H Endothelium-dependent contraction induced by platelet-derived substances in canine basilar arteries. J. Pharmacol. Exp. Ther. 1990 255 182–186.
  • Cardin, JP Jr Ross, MG Ervin, MG Fetal and maternal response to I.V. infusion of a thromboxane A2 synthetase inhibitor. Am. J. Obstet. Gynecol. 1990 163 1345–1349.
  • Montalescot, G Lowenstein, E Ogletree, ML TXA2 receptor blockade prevents pulmonary hypertension induced by heparinprotamine rections in awake sheep. Circulation 1990 82 1765–1777.
  • Woodward, DF Nieves, AL Williams, LS Thromboxane A2-mimetics are potent microvascular permeability factors in the conjunction. J. Pharmacol. Exp. Ther. 1990 255 23–27.
  • Elliott, GR Lauwen, AP Bonta, IL The effect of acute feeding of carnitine, acetyl carnitine, and propionyl carnitine on basal and A23187-stimulated eicosanoid release from rat carrageenan-elicited peritoneal macrophages. Br. J. Nutr. 1990 64 497–503.
  • McColl, T O'Leary, D Bloomfield, J O'Morain, CA Eicosapentaenoic acid (EPA). Gastroenterology 1988 94 A294.
  • Prichard, PJ Daneshmend, TK Willars, JE Fish oil for inflammatory bowel disease? Gut 1987 28 A1391.
  • Brogan, M Hiserodt, J Oliver, M The effect of 6 MP on NK cell activities in Crohn's disease. J. Clin. Immunol. 1985 5 204–211.
  • Shih, WWH Ellison, GW Myers, IN Locus of selective depression of human NK cells by azathioprine. Clin. Immunol. Immunopathol. 1982 23 672–681.
  • Gibson, PR Jewell, DP Local immune mechanisms in inflammatory bowel disease and colorectal carcinoma. Gastroenterology 1986 90 12–19.
  • Leman, B Shanehan, F Targan, S Serial study of immunological alteration in patients with inflammatory bowel disease on long-term treatment with 6-MP: Effect on CTL. Gastroenterology 1988 94 A255.
  • O'Donoohue, DP Dawson, AM Powell-Tuck, J Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978 2 955–957.
  • Willoughby, JM Beckett, J Kumar, P Dawson, AM Controlled trial of azathioprine in Crohn's disease. Lancet 1971 2 944–947.
  • Kirk, AP Lennard-Jones, JE Controlled trial of azathioprine in chronic ulcerative colitis. Br. Med. J. 1982 284 1291–1292.
  • Present, DH Chapman, ML Rubin, PH Efficacy of 6-mercaptopurine in refractory ulcerative colitis. Gastroenterology 1988 94 A359.
  • Present, DH Korelitz, BI Wisch, JL Treatment of Crohn's disease with 6-mercaptopurine-long-term randomized double-blind study. N. Engl J. Med. 1980 302 981–987.
  • Summers, RW Switze, DM Sessions, JG National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979 77 847–869.
  • Bianchi, PA Mondelli, DM Quatro di Palo, F Ranzi, T Cyclosporin A for Crohn's disease. Lancet 1984 1 1242.
  • Allam, BF Tillmann, JE Thomson, TJ Effective intravenous cyclosporin A in a patient with severe Crohn's disease on parenteral nutrition. Gut 1987 28 1166–1169.
  • Gupta, S Keshavarzian, A Hodgson, HJF Cyclosporin A in ulcerative colitis. Lancet 1984 2 1277–1278.
  • Bunjes, D Hardt, C Rollinghoff, M Wagner, H Cyclosporin A mediates immunosuppression of primary CTL responses by impairing release of IL-1 and IL-2. Eur: J. Immunol. 1981 11 657–661.
  • Harris, DT Kozumbo, WJ Cerutti, PA Cerottini, JC Mechanism of Cyclosporin A-induced immunosuppression. Cell. Immunol. 1987 109 104–114.
  • Cooper, HS Murthy, SN Sedergran, DJ Morphological studies of dextran sulfate sodium induced colitis in mice. Gastroenterology 1991 100 A564.
  • Shim, H Murthy, S Cooper, H Ibrahim, S Intracolonic cyclosporin (CSP) accelerates healing of experimental colitis induced by dextran sulfate in the mouse. Gastroenterology 1991 100 A841.
  • Murthy, SNS Shim, H Shah, R Low doses of intracolonic cyclosporin enhance healing in rodent IBD. 5th International Poster Session Inflammation Research Association 1990 Abstract #196.
  • Sanborn, WJ Strong, RM Forland, SC Cyclosporin pharmacokinetics and colon tissue concentration after oral administration or retention enema in man Gastroenterology 1990 98 A202.
  • Stange, EF Fleig, WE Rekhlaw, E Ditschuneit, H Cyclosporin A treatment in inflammatory bowel disease. Dig. Dis. Sci. 1989 34 1387–1392.
  • Kino, T Hatanaka, H Hashiwoto, M FK506, a novel immunosuppressant isolated from a streptomyces. I: Fermentation, isolation and physicochemical and biological characteristic. J. Antibiotics (Tokyo) 1987 40 1249.
  • Kino, T Inamura, N Sakai, F Effect of FK506 on human MLC reaction in vitro. Transplant. Proc. 1987 19 36.
  • Kino, T Hatanaka, H Miyata, H FK506, a novel immunosuppressant isolated from a Streptomyces. II. immunosuppressive effect of FK506 in vitro. J. Antibiotics (tokyo) 1987 40 1256.
  • Arita, C Hotokebuchi, T Miyahara, K Inhibition by FK506 of established lesion of collagen-induced arthritis in rats. Clin. Exp. Immunol 1990 82 456–461.
  • Oppenheim, JJ Koracs, EJ Matsushima, K Duram, SK There is more than one interleukin 1. Immunol Today 1986 7 45–56.
  • Billingham, MEJ Cytokines as inflammatory mediators. Brit. Med. Bull. 1987 43 350–370.
  • Epstein, LB Ramila, P Tumour necrosis factor as immunomodulator and mediator of monocyte toxicity by itself, β-interferon, and interleukin 1. Nature 1986 323 86–89.
  • Pohlman, TH Stanness, KA Beatty, PG An endothelial cell surface factor induced in vitro by lipopolysaccharide, interleukin-1, and tumour necrosis factor α increases neutrophil adherence by a CDN-18-dependent mechanism. J. Immunol. 1986 136 4548–4553.
  • Dinarello, CA Interleukin-1. Rev. Infect. Dis 1984 6 51–95.
  • Gordon, AH Koj, A The acute phase response to injury and infection. Res. Mono. Cell Tissue Physiol. 1985 10.
  • Durum, SK Schmidt, JA Oppenheim, JJ Interleukin 1: An immunological perspective. Ann. Rev. Immunol. 1985 3 263–287.
  • Dinarello, CA Immunomodulators in clinical medicine. Ann. Intern. Med. 1987 106 421–433 Interleukin-1 as an endogenous immunoadjuvant. pp. 426–427. In: Fauci, AS, moderator.
  • Liao, Z Grimshaw, RS Rosenstreich Identification of a specific interleukin-1 inhibitor in the urine of febrile patients. J. Exp. Med. 1984 159 126–136.
  • Tiko, K Tiko, ML Liu, S Skosey, JL Normal human neutrophils are a source of a specific interleukin-1 inhibitor. J. Immunol. 136 3686–3692.
  • Cominelli, F Nast, CC Gentilini, P Regulation of eicosanoid production in rabbit colon by interleukin-1. Gastroenterology 1989 97 1400–1405.
  • Cominelli, F Nast, CC Llerena, R Interleukin-1 suppresses inflammation in rabbit colitis. Mediation by endangenous prostaglandins. J. Clin. Invest. 1990 85 582–586.
  • Mahida, YR Gallagher, A Kurlak, L Hawkey, CJ Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease. Clin. Exp. Immunol. 1990 82 75–80.
  • Clapp, NK Henke, MA Hansard, RM Inflammatory mediators in cotton-top tamarins with acute and chronic colitis. 5th International Poster Session Inflammation Research Association 1990 142.
  • DiJoseph, JF Caccese, RG Skotnicki, JS Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989. 5th International Poster Session Inflammation Research Association 1990 178.
  • Dong, MK Wilburn, DJ Conroy, MC Gilbertsen, RB Blockade of interleukin-2 (IL-2) production by CI-959, a novel cell activation inhibitor. 5th International Poster Session Inflammation Research Association 1990 46.
  • Thomas, TK Will, PC Strivastava, A Evaluation of an interleukin-1 receptor antagonist (IL-1va) in the rat acetic-acid-induced colitis model. 5th International Poster Session Inflammation Research Association 1990 150.
  • Bessin, P Bonnet, D Thiboudeau, B INSERM Symposium #23 Benneisti, J, Arnoux, B Elsevier 1983 343–356.
  • Vargaftig, BB Braquet, PG PAF-acethir today-relevance for acute experimental anaphylaxis. Brit. Med. Bull 1987 43 312–335.
  • Wengrower, D Eliakim, R Karmeli, F Pathogenesis of ulcerative colitis: Enhanced formation of inositol triphosphates and PAF. Gastroenterology 1987 92 1691.
  • Wallace, JL Leukotrienes and PAF as mediators of gastrointestinal ulceration and inflammation Therapeutic Approaches to Inflammatory Diseases Lewis, AJ, Doherty, NS, Ackerman, NR Elsevier 1989 157–169.
  • Wallace, JL Release of PAF and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can. J. Physiol. Pharmacol 1988 66 422–425.
  • Will, PC Thomas, TK Iverson, L Platgelet activating factor (PAF) as a proinflammatory mediator in acetic acid induced colitis in the rat. 5th International Poster Session Inflammation Research Association 1990 144.
  • Burger, RM Berkowitz, AR Peisach, J Howitz, B Origin of malondialdehyde from DNA degraded by Fe(II) bleomycin. J. Biol. Chem. 1980 255 11832–11838.
  • Ames, BN Dietary carcinogens and anticarcinogens. Science 1983 221 1256–1264.
  • Aust, SD Svingen, BA The role of iron in enzymatic lipid peroxidation Free Radicals in Biology Prior, WA Academic Press 1982 1–28.
  • Hooper, C Free radicals: Research on biochemical bad boys comes of age. The Journal of NIH Research 1989 1 101–106.
  • Grisham, MB von Ritter, C Smith, BF Interaction between oxy radicals and gastric mucin. Am. J. Physiol 1987 253 G93–G96.
  • Halliwell, B Sulfasalazine and oxidant scavenging in ulcerative colitis. Lancet 1987 12 635.
  • Craven, PA Pfanstiel, J Saito, R Actions of sulfasalazine and 5-ASA as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity. Gastroenterology 1987 92 1998–2008.
  • Tamai, H Kachur, JF Grisham, MB Gaginella, TS Neutrophil-derived oxidants are scavenged by 5-ASA: Possible relationship to its therapeutic action in inflammatory bowel disease. 5th International Poster Session Inflammation Research Association 1990 17.
  • Dowling, EJ Griffiths, HR Lunee, J Blake, DR Oxidative damage to lipids, protein, and carbohydrate in an animal model of inflammation: Protection by Ebselen. 5th International Poster Session Inflammation Research Association 1990 Abstract #193.
  • Oda, T Akaike, T Hamamoto, T Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 1989 244 974–976.
  • Hall, ED Pazara, KE Braughler, JH 21-Aminosteroid lipid perixidation inhibitor U74006F protects against cerebral ischaemia in gerbils. Stroke 1988 19 997–1001.
  • Emeritt, J Loeper, J Chomette, G Superoxide dismutases in the treatment of post radiotherapeutic necrosis and of Crohn's disease. Bull. Eur. Physiopathol. Respir. 1981 17 287–288.
  • Perkau, A Scientific basis for the clinical use of superoxide dismutase. Cancer Treatment Review 1986 13 17–44.
  • Emerit, I Emerit, J Leug, A Beck, M Chromosomal breakage in Crohn's disease: Anticlastogenic effect of D-penicillamine and L-cysteine. Human Genetics 1972 16 313–322.
  • Grisham, MB Granger, DN Neutrophilmediated mucosal injury - role of reactive oxygen metabolites. Dig. Dis. Sci. 1988 33 6S–15S.
  • Bennett, JD Use of α-tocopherolquinone in the treatment of ulcerative colitis. Gut 1986 27 695–697.

References to Patent literature

  • ICI PLC EP 0385679 A Sept 1990 AG0450 Fast Alert.
  • ICI PLC EP 0385663 A: AG0448 Fast Alert Sept 1990.
  • Terumao KK EP 0402469 A: AG0777 Dec 1990 Fast Alert.
  • SCRAS GB 2231330 A: AG0666 Nov 1990 Fast Alert.
  • SCRAS GB 2229723 A: AG0566 Oct 1990 Fast Alert.
  • Boehringer Ingelheim AG WO 90 12013: AG0646 Nov 1990 Fast Alert.
  • University of Texas EP 0401952 A: AG0752 Dec 1990 Fast Alert.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.